Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.44) by 20.45 percent. This is a 51.39 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $30.76 million which beat the analyst consensus estimate of $30.24 million by 1.73 percent.